Company / Depreciation & Amortization
KalVista Pharmaceuticals, Inc. Depreciation & Amortization History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$941.0K
FY2025
5-year range
$564.0K / $941.0K
FY2021-FY2025
Trend
+0.0%
vs FY2024
Sector context
#125 of 163
Health Care
What the data says
KalVista Pharmaceuticals, Inc.'s depreciation & amortization of $941,000 is lower than 77% of companies in the Health Care sector (FY2025). Increased from $816,000 to $941,000 over the past 2 years.
Based on SEC 10-K filings.
$941,000 in FY2025 with a 5-year CAGR of +11.9%.
Increased from $816,000 to $941,000 over the past 2 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- +9.4%
- 5-Year CAGR
- +11.9%
- 10-Year CAGR
- -
Sector benchmark
Top 23% in Health CareTop 23% of 163This company $941.0K Sector average $219.4M
▼
-99.6% below sector average
Key checks
Key Insights
- 5-year CAGR of +11.9%, indicating consistent growth.
- In FY2025, depreciation & amortization increased 0.0% year-over-year.
- Ranks #125 out of 163 companies in the Health Care sector.
- Lowest depreciation & amortization in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score -3.72 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $941.0K | +0.0% |
| FY2024 | $941.0K | +15.3% |
| FY2023 | $816.0K | +13.6% |
| FY2022 | $718.0K | +27.3% |
| FY2021 | $564.0K | +5.0% |
| FY2020 | $537.0K | +1242.5% |
| FY2019 | $40.0K | +21.2% |
| FY2018 | $33.0K | -81.7% |
| FY2017 | $180.0K | +350.0% |
| FY2016 | $40.0K | +5.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026